Clinical trial · Observational
Sentinel Lymph Node Biopsy Versus Lymphadenectomy in Endometrial Cancer
Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early Stage Endometrial Cancer
NCT05048173CI-TRIAL-00069652completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare sentinel lymph nodes biopsy versus comprehensive lymphadenectomy in patients with early stage endometrial cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early Stage Endometrial Cancer | — | UNRESOLVED | — |
| Lymphadenectomy | — | UNRESOLVED | — |
| Sentinel Lymph Nodes | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lymphadenectomy | Procedure | — | UNRESOLVED |
| Sentinel lymph node mapping and biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Sentinel lymph node group
- description
- woman who had sentinel lymph node mapping and biopsy
- interventionNames
- Procedure: Sentinel lymph node mapping and biopsy
- label
- Lymphadenectomy group
- description
- woman who underwent traditional pelvic lymphadenectomy without sentinel lymph node mapping
- interventionNames
- Procedure: Lymphadenectomy
Primary outcomes (2)
- measure
- progression free survival
- timeFrame
- 4 years
- description
- The length of time from the day of operation till recurrence or last follow up
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * ≧ 20 years * early stage endometrial cancer (FIGO stage I) Exclusion Criteria: * Did not receive a complete course of treatment in this hospital, interrupted the treatment halfway (except if the disease continued to deteriorate or caused death during treatment), and did not follow up in this hospital after the course of treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.